Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness

Journal of Diabetes Investigation

Volumn 4, Issue 4, 2013, Pages 334-343

  Shin, Jeong Ah ^a   Lee, Jin Hee ^a   Lim, Sun Young ^a   Ha, Hee Sung ^a   Kwon, Hyuk Sang ^a   Park, Yong Moon ^a   Lee, Won Chul ^a   Kang, Moo Il ^a   Yim, Hyeon Woo ^a   Yoon, Kun Ho ^a   Son, Ho Young ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Metabolic syndrome; Risk factor; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; DIET RESTRICTION; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYNDROME DELINEATION;

EID: 84880168328     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12075     Document Type: Review

References (72)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
2. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-443.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
4. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
5. Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991; 34: 356-361.
6. Després J, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
7. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998; 83: 2773-2776.
8. Hu G, Qiao Q, Tuomilehto J, et al. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia 2004; 47: 1245-1256.
9. Chen SJ, Yen CH, Huang YC, et al. Relationships between inflammation, adiponectin, and oxidative stress in metabolic syndrome. PLoS One 2012; 7: e45693.
10. Devaraj S, Valleggi S, Siegel D, et al. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep 2010; 12: 110-118.
11. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087-2094.
12. Lambert GW, Straznicky NE, Lambert EA, et al. Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications. Pharmacol Ther 2010; 126: 159-172.
13. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
14. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, et al. The metabolic syndrome: a concept hard to define. Arch Med Res 2005; 36: 223-231.
15. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
16. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 2002; 25: 1790-1794.
17. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-1132.
18. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care 2003; 26: 933-939.
19. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
20. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062.
21. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
22. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011; 34: 216-219.
23. Lim S, Shin H, Song JH, et al. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care 2011; 34: 1323-1328.
24. Kim HM, Park J, Kim HS, et al. Prevalence of the metabolic syndrome in Korean adolescents aged 12-19 years from the Korean National Health and Nutrition Examination Survey 1998 and 2001. Diabetes Res Clin Pract 2007; 75: 111-114.
25. You MA, Son YJ. Prevalence of metabolic syndrome and associated risk factors among Korean adolescents: analysis from the Korean national survey. Asia Pac J Public Health 2012; 24: 464-471.
26. Cai H, Huang J, Xu G, et al. Prevalence and determinants of metabolic syndrome among women in Chinese rural areas. PLoS One 2012; 7: e36936.
27. Nestel P, Lyu R, Low LP, et al. Metabolic syndrome: recent prevalence in East and Southeast Asian populations. Asia Pac J Clin Nutr 2007; 16: 362-367.
28. Nishimura R, Nakagami T, Tominaga M, et al. Prevalence of metabolic syndrome and optimal waist circumference cut-off values in Japan. Diabetes Res Clin Pract 2007; 78: 77-84.
29. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
30. Ninomiya T, Kubo M, Doi Y, et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study. Stroke 2007; 38: 2063-2069.
31. Hwang YC, Jee JH, Oh EY, et al. Metabolic syndrome as a predictor of cardiovascular diseases and type 2 diabetes in Koreans. Int J Cardiol 2009; 134: 313-321.
32. Wilson PW. Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinol Metab Clin North Am 2004; 33: 467-481.
33. Wilson PW, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and Type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
34. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31: 1898-1904.
35. Hanley AJ, Karter AJ, Williams K, et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2005; 112: 3713-3721.
36. Ley SH, Harris SB, Mamakeesick M, et al. Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community. CMAJ 2009; 180: 617-624.
37. Cameron AJ, Zimmet PZ, Soderberg S, et al. The metabolic syndrome as a predictor of incident diabetes mellitus in Mauritius. Diabet Med 2007; 24: 1460-1469.
38. Hadaegh F, Ghasemi A, Padyab M, et al. The metabolic syndrome and incident diabetes: assessment of alternative definitions of the metabolic syndrome in an Iranian urban population. Diabetes Res Clin Pract 2008; 80: 328-334.
39. Schmidt MI, Duncan BB, Bang H, et al. Identifying individuals at high risk for diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2005; 28: 2013-2018.
40. Cheung BM, Wat NM, Man YB, et al. Development of diabetes in Chinese with the metabolic syndrome: a 6-year prospective study. Diabetes Care 2007; 30: 1430-1436.
41. Lorenzo C, Williams K, Hunt KJ, et al. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30: 8-13.
42. Cameron AJ, Magliano DJ, Zimmet PZ, et al. The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. J Intern Med 2008; 264: 177-186.
43. Hanson RL, Imperatore G, Bennett PH, et al. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 2002; 51: 3120-3127.
44. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003; 26: 3153-3159.
45. Stern MP, Williams K, González-Villalpando C, et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 2676-2681.
46. Meigs JB, Rutter MK, Sullivan LM, et al. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007; 30: 1219-1225.
47. Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 2644-2650.
48. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419.
49. Elwood PC, Pickering JE, Fehily AM. Milk and dairy consumption, diabetes and the metabolic syndrome: the Caerphilly prospective study. J Epidemiol Community Health 2007; 61: 695-698.
50. Macchia A, Levantesi G, Borrelli G, et al. A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione scoring. Am Heart J 2006; 151: e7-e754, e17.
51. Salminen M, Kuoppamäki M, Vahlberg T, et al. Metabolic syndrome defined by modified International Diabetes Federation criteria and type 2 diabetes mellitus risk: a 9-year follow-up among the aged in Finland. Diab Vasc Dis Res 2013; 10: 11-16. doi: 10.1177/1479164112442077.
52. Povel CM, Beulens JW, van der Schouw YT, et al. Metabolic syndrome model definitions predicting type 2 diabetes and cardiovascular disease. Diabetes Care 2013; 36: 362-368. doi: 10.2337/dc11-2546.
53. Hanley AJ, Williams K, Festa A, et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005; 54: 3140-3147.
54. Pladevall M, Singal B, Williams LK, et al. A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care 2006; 29: 113-122.
55. Alexander CM, Landsman PB, Grundy SM. Metabolic syndrome and hyperglycemia: congruence and divergence. Am J Cardiol 2006; 98: 982-985.
56. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44(Suppl 2): S14-S21.
57. Woodward M, Zhang X, Barzi F, et al. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 2003; 26: 360-366.
58. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
59. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162-172.
60. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
61. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
62. Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159: 1104-1109.
63. Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. Diabetes Care 2003; 26: 861-867.
64. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250.
65. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-1076.
66. Takeuchi H, Saitoh S, Takagi S, et al. Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men-the Tanno and Sobetsu Study. Hypertens Res 2005; 28: 203-208.
67. Andreadis EA, Tsourous GI, Tzavara CK, et al. Metabolic syndrome and incident cardiovascular morbidity and mortality in a Mediterranean hypertensive population. Am J Hypertens 2007; 20: 558-564.
68. Song Y, Manson JE, Meigs JB, et al. Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women. Am J Cardiol 2007; 100: 1654-1658.
69. Ingelsson E, Sullivan LM, Murabito JM, et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes 2007; 56: 1718-1726.
70. Kokubo Y, Okamura T, Yoshimasa Y, et al. Impact of metabolic syndrome components on the incidence of cardiovascular disease in a general urban Japanese population: the suita study. Hypertens Res 2008; 31: 2027-2035.
71. Arnlöv J, Ingelsson E, Sundström J, et al. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010; 121: 230-236.
72. Wang JJ, Li HB, Kinnunen L, et al. How well does the metabolic syndrome defined by five definitions predict incident diabetes and incident coronary heart disease in a Chinese population? Atherosclerosis 2007; 192: 161-168.